This page is updated frequently with new Proliferation-related patent applications.
| Screening assay for agents that influence beta cell number and/or phenotype|
The present invention in general relates to a method for identifying compounds that influence beta cell number and/or phenotype, more in particular beta cell differentiation, proliferation and/or expansion. Said method comprising culturing beta cells or precursors thereof in 5 medium comprising glucose, and determining the ability of said compound to induce the glucocorticoid receptor dependent-transactivation pathway in said beta cells.
| Compositions and methods of using transposons|
The present invention provides compositions and methods of using transposons. In one aspect, methods are disclosed that are useful for identifying negatively selected genes in an insertional mutagenesis screen.
| Method of producing fr901228|
Depsipeptides and congeners thereof are disclosed having structure (i), wherein m, n, p, q, x, r1, r2 and r3 are as defined herein. These compounds, including fr901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant.
Astellas Pharma Inc.
| Method of using a mir172 molecule for decreasing inflammation|
An exemplary embodiment relates to a method of using a plant-derived mir172 molecule or its synthetic equivalent, selected from amongst mir172a or mir172b, for decreasing inflammatory processes in an organism, a method of decreasing b and t lymphocyte proliferation, as well as a method of reducing protein fan (factor associated with neutral sphingomyelinase activation) level. Exemplary embodiments provide a novel therapeutic method based on mirna molecules, which through the interaction with mrna encoding fan protein, negatively regulate its expression and decrease the inflammatory response of the organism..
Uniwersytet Im. Adama Mickiewicza W Poznaniu
| Method of improving the yield of algae production|
The present disclosure discloses a method of improving the yield of algae from an environment consisting of diatoms. This selective culturing of algae from a mixed environment is achieved by the use of a urea cycle pathway inhibitor.
Reliance Industries Limited
| Inhibition of pulmonary fibrosis with nutlin-3a and peptides|
In fibrotic lung fibroblasts, basal levels of p53 protein (and mir-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of upa and upar, or concurrent induction of pai-1. These changes contribute to excessive fl-fibroblast proliferation and production of extracellular matrix (ecm), and, therefore, pulmonary fibrosis.
Board Of Regents, The University Of Texas System
| Trail enhancers for the selective killing of cancer cells|
The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an n-acyl homoserine lactone analog (ahl), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (tnf) related apoptosis inducing ligand (trail) to the patient. Novel bioactive analogs of an n-acyl homoserine lactone are also provided..
The Scripps Research Institute
| Containers designed to keep food fresher|
Containers and bags are designed to keep food fresher by including a substance such as zeolite, which inhibits bacteria from spoiling food. This matter absorbs or adsorbs ethylene gas or other gases that age food.
| Method for obtaining a spray-on cellular compound of human fibroblasts and keratinocytes in solution and the use thereof as a regenerative agent in skin lesions|
The present invention relates to a process for obtaining a compound of cellular spraying for fibroblasts and human keratinocytes and its use as regenerative agent of cutaneous lesions, mainly in diabetic ulcers, first, second, and third grade burns, and a substitute for the use of flaps techniques. The process for obtaining a compound of cellular spraying for fibroblasts and human keratinocytes includes the steps of separating the dermis and epidermis layers, incubation of the epidermis layer, disintegration of dermis layer and proliferation of fibroblasts, disintegration of the epidermis layer, proliferation of keratinocytes in suspension, preparation of the cross-linking reaction agent solution of the cellular spraying solution, and preparation of cellular spraying solution.
| Hand disinfectant|
The invention provides a skin disinfectant for treating skin with eczema, preventing bacterial proliferation, and removing biofilm. Compositions of the invention include hypochlorous acid, acetic acid, water, and one or more additives or excipients.
Wiab Water Innovation Ab
Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
The described invention provides methods for modulating gene expression of a gene related to proliferation of a population of tumor cells. The method entails administering a therapeutic amount of a therapeutic compound to a cell, a tissue, or a mammal, wherein the therapeutic amount of the therapeutic compound is effective to suppress methyltransferase activity of a protein arginine methyltransferase.
Epinova Therapeutics Corp.
Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same
The present invention relates to a new use of panduratin derivatives or a kaempferia pandurata extract comprising the same. More particularly, the present invention relates to a composition for improving wrinkles and/or preventing aging, which comprises a panduratin derivative or a kaempferia pandurata extract comprising the same.
Newtree Co., Ltd.
Novel selenium-containing compound
The invention provides a method of improving an antioxidant effect in a redox pathway that involves selenium in a subject, an in vitro method of inhibiting oxidation in a cell or tissue, and an in vitro method of promoting proliferation of a cell, by use of a selenium-containing compound of chemical formula 1:. .
Fisheries Research Agency
Antibodies directed against icos and uses thereof
The present invention provides antibodies directed against icos or a derivative thereof which neutralize icos engagement on treg by inhibiting the fixation between icos and icos-l and abrogate proliferation of treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against icos or a derivative thereof which induce il-10 and ifnγ production, induce cd4+ t cells proliferation, reduce tconv proliferation, and increase the immunosuppressive function of treg..
Centre Leon Berard
Pharmaceutical compositions and methods
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3a4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3a4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
Use of mks inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (nsclc) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence yaraaarqarakalarqlgvaa (seq id no: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof..
Moerae Matrix, Inc.
Compositions and methods for altering human cutaneous microbiome to increase growth of staphylococcus epidermidis and reduce staphylococcus aureus proliferation
An antibacterial composition comprising arginine bicarbonate, zinc carbonate, preferably arginine bicarbonate and zinc carbonate (abzc), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic staphylococcus aureus bacteria by promoting the growth of non-pathogenic staphylococcus epidermidis bacteria.. .
The Research Foundation For The State University Of New York
Pharmaceutical compositions and methods
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3a4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3a4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
Crk - a novel target for cancer therapy
The invention features a method of identifying a therapeutically active compound that inhibits apoptotic compensatory signaling complex (acsc)-induced cell proliferation.. .
Rush University Medical Center
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Methods for inducing cardiomyocyte proliferation
Methods for inducing cardiomyocyte proliferation, e.g., in vivo, by administering a composition comprising mirna17-92 cluster oligonucleotides, e.g., mir-19a oligonucleotides, mir-19b oligonucleotides, or both mir-19a and mir-19b oligonucleotides.. .
Children's Medical Center Corporation
Humanized and variant anti-vegf antibodies and various uses therefor are disclosed. The anti-vegf antibodies have strong binding affinities for vegf; inhibit vegf-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo..
The invention relates to a cell-penetrating peptide, optionally linked to a pro-apoptotic peptide, useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.. .
Thieno- and pyrrolopyrimidine analogues as anticancer agents and methods of use thereof
The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.. .
University Of Maryland, Baltimore County
Novel compositions, uses and methods for making them
Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same..
Heterocyclic compounds and methods for their use
The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration..
Modulation of splenocytes in cell therapy for traumatic brain injury
The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of cd4+ and cd8+ t-cells, increase il-4 and il-10, and increase m2:m1 macrophage ratio at the site of injury.
Abt Holding Company
Methods of treating keratin hyperproliferation disorders using mtor inhibitors
A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mtor inhibitor to a subject afflicted with the hyperproliferation disorder.
The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ≧1% at 25° c. And neutral ph and having a melting temperature (gel to sol) of 35 to 60° c.
Biotec Pharmacon Asa
Antimicrobial cosmetic container containing impregnating material
Provided is a cosmetic container containing an antimicrobial impregnating material made of a polycaprolactone polyol foam in an antimicrobial sealed container, and more particularly, an antimicrobial cosmetic container containing an antimicrobial material which may reinforce disadvantages of polyester polyol foam- and polyether polyol foam-type impregnating materials, such as water resistance (hydrolysis resistance) and oil resistance and inhibit the proliferation of microorganisms.. .
Dmt Co., Ltd.
Compositions and methods for treating cancer and modulating stress granule formation
The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-adp-ribose polymerase (parp) inhibitors, one or more parp activators, one or more poly-adp-ribose glycosylase (parg) activators, and/or one or more poly-adp-ribose glycohydrolase arh3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells.
Massachusetts Institute Of Technology
Defined media for expansion and maintenance of pluripotent stem cells
The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages.
Janssen Biotech, Inc.
Cell culture medium and bioprocess optimization
The invention provides a chemically defined cell culture media and methods of using the media. The invention also provides an inverse screen to identify small molecules and synergies stimulating proliferation in a chemically defined medium.
University Of Notre Dame Du Lac
Culture medium for establishing neuroepithelial stem cells, establishing neuroepithelial stem cells, and applications thereof
The present invention discloses a culture medium for establishing neuroepithelial stem cells, a method for establishing neuroepithelial stem cells, and the applications thereof, wherein the culture medium comprises differentiation culture medium for inducing and differentiating pluripotent stem cells to elementary neuroepithelial stem cells as well as proliferation culture medium for amplifying the elementary neuroepithelial stem cells; and the pluripotent stem cells can be differentiated to the elementary neuroepithelial stem cells in the differentiation culture medium. While the elementary neuroepithelial stem cells have the functions of the neuroepithelial stem cells, they cannot be stably amplified in long term culture under the conventional culture conditions, however they are maintained the stability properties in long term culture in the proliferation culture medium.
Yunnan Key Lab Of Primate Biomedicine Research
Anti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
Chromene derivatives as inhibitors of tcr-nck interaction
And which present the ability to inhibit the lymphocytes proliferation mediated by the tcr interaction with nck, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions wherein said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.. .
Regenerative prostheses as alternatives to donor corneas for transplantation
The present invention relates to a corneal implant comprising a matrix material and a core part wherein the core part is arranged essentially in the middle of the matrix material. The core part is anti fouling in order to stop cell proliferation across said part.
The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations..
Boehringer Ingelheim International Gmbh
Nanogel-mediated drug delivery
Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof.
The Cleveland Clinic Foundation
Methods of treatment with drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
A drug eluting stent can include a stent body having a polymeric coating with a lipophilic and/or hydrophilic element. A drug that has a bioactivity that inhibits cell proliferation can be disposed in the polymeric coating.
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Method for biologically combating naegleria fowleri, and disinfecting agent containing protozoa of the species willaertia magna
The invention relates to a process for combating the proliferation of the naegleria genus and in particular of the species naegleria fowleri, with the exception of the treatment methods applied to the human or animal body, characterized in that it uses protozoa of the species willaertia magna, and also a disinfecting agent containing such protozoa.. .
Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
The present disclosure relates to the finding that microrna-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microrna-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of cutl1, arnt1, picalm, jarid2, pu.1, csf1r, hif1α, sla, cepbβ, and bach1, and the like..
California Institute Of Technology
Compounds for inhibiting cell proliferation in egfr-driven cancers
Wherein the variables are as defined herein.. .
Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
And w, z, xy, ry1, ry2 and ry3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers..
Fused heterocyclic compound, preparation method therefor, pharmaceutcial composition, and uses thereof
Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula i, formula ii, or formula iii.
Shanghai Yingli Pharmaceutical Co., Ltd.
Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction
And that present the capacity to inhibit the proliferation of lymphocytes mediated by the nck interaction with tcr, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions where said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.. .
Methods and systems for treatment of spinal disorders using trans-spinal direct current stimulation
Methods, systems and devices are disclosed for treating a spinal disorder by applying a source of direct current to a spinal cord in animals, including humans. Trans-spinal direct current stimulation (tsdcs) uses direct current via cathodal and/or anodal stimulation to induce cell proliferation, cell differentiation, and/or cell migration at or near the area of the spinal cord being treated, and up-regulates or down-regulates protein expression by cells at or near the area of the spinal cord being treated..
Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (pepst) and exciton-plasmon enhanced phototherapy (epep)
The use of plasmonics enhanced photospectral therapy (pepst) and exiton-plasmon enhanced phototherapy (epep) in the treatment of various cell proliferation disorders, and the pepst and epep agents and probes used therein.. .
Anticancer composition containing mixed herbal medicine extract as active ingredient
An embodiments of the invention relates to a composition containing, as an active ingredient, a mixed extract of astragalus membranaceus, angelica gigas, and trichosanthes kirilowii, for preventing or treating cancer. The mixed extract of astragalus membranaceus, angelica gigas, and trichosanthes kirilowii according to this embodiment of the invention does not impact normal cell growth, while having an anticancer effect which specifically inhibits the proliferation of cancer cells, and an excellent effect of inhibiting metastasis of cancer cells, and thus can be useful in preventing or treating cancer and supplementing cancer treatment..
University-industry Cooperation Group Of Kyung Hee University
Compositions and methods for inhibition of pathogenic bacterial growth
Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.. .
Seres Therapeutics, Inc.
Compositions and methods for mesenchymal/stromal stem cell rejuvenation and tissue repair by enhanced co-expression of telomerase and myocardin
A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging.
Biocampatible polymer coated silver prussian blue nanoparticles (spb-nps: ag3 [fe (cn) 6])
The present invention relates to highly biocompatible or nontoxic pvp (poly(n-vinyl-2-pyrrolidone) coated silver prussian blue nanoparticles (spb-nps: ag3[fe(cn)6] where pvp acts as stabilizing or capping agent. The as-synthesized nanoparticles (spb-nps) have been thoroughly characterized by several analytical tools.
Council Of Scientific & Industrial Research
Inhibition of sgk1 in the treatment of heart conditions
The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of sgk1, including long qt syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by sgk1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure.
Beth Israel Deaconess Medical Center, Inc.
Pri-mirna libraries and methods for making and using pri-mirna libraries
Provided are methods for the design, preparation, and use of non-native pri-micrornas (pri-mirnas), pri-microrna (pri-mirna) scaffolds, and libraries of non-native pri-mirnas employing pri-mirna scaffolds. Also provided are methods for identifying non-native pri-mirnas, combinations of two or more non-native pri-mirnas, and mirnas derived from the processing of such non-native pri-mirnas, which mirnas exhibit one or more desired functional activities.
Chimeric antigen receptor
The present invention provides a chimeric antigen receptor (car) comprising: (i) a b cell maturation antigen (bcma)-binding domain which comprises at least part of a proliferation-inducing ligand (april); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular t cell signaling domain. The invention also provides the use of such a t-cell expressing such a car in the treatment of plasma-cell mediated diseases, such as multiple myeloma..
Ucl Business Plc
Therapy for promoting cell growth
There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells..
Moleac Pte. Ltd.
Chemically defined culture medium for stem cell maintenance and differentiation
The present invention is directed to a low protein medium for the culture of pluripotent stem cells comprising one or more polysaccharides. The medium of the present invention can support cell culture objectives, for example cell survival, maintenance, passaging, proliferation, pluripotency, cloning, differentiation and induced pluripotent stem (ips) cell derivation..
The U.s.a., As Represented By The Secretary, Department Of Health & Human Services
Cyclic peptide conjugates and methods of use
The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).. .
Thieno[2,3-e]indole derivatives as new antitumor agents
The present invention relates to a novel class of alkylating agents comprising a thieno[2,3-e]indole moiety tethered to a dna-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them.
Nerviano Medical Sciences S.r.l.
Alternative magnetic stimulating system for preventing or treating brain tumor growth
Disclosed herein is a bidirectional alternating application system for preventing or treating a brain tumor caused by malignant glioma cells in animals. The bidirectional alternating magnetic field application system can apply a magnetic field having weak intensity and low frequency to patients in need of the prevention or treatment of brain tumor to thereby specifically inhibit the proliferation and mobility of glioma cells without causing any damage to normal cells.
Sangji University Industry Academic Cooperation Foundation
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
Methods of regenerating tissue using progenitor cells in combination with primary cells from a target tissue are disclosed. The progenitor cells catalyze proliferation and tissue production by primary cells allowing the use of fewer primary cells from a target tissue for effective tissue regeneration.
The Board Of Trustees Of The Leland Stanford Junior University
Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a lif preparation, a bmp preparation, a bmpr signalling activator, and a lifr signalling activator.
Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment
Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations..
Use of cardiotrophin to modulate stem cell proliferation
Methods of promoting stem cell proliferation by contacting the cells with cardiotrophin-1 (ct-1) are provided. The methods may further include contacting the stem cells with one or more stem cell modulators that promote differentiation of the stem cells.
Ottawa Hospital Research Institute
Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
A method for promoting biological activity uses a filter system to increase cell production of a fed batch bioreactor. The filter system cycles bioreactor fluid through a hollow fiber tangential flow filter which separates metabolic wastes (as well as proteins) from cells produced in bioreactor and returned to fed batch bioreactor, improving cell production in the fed batch bioreactor.
Method of treating glioma
Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (bdnf), or brevican, to a patient with a glioma.
The Board Of Trustees Of The Leland Stanford Junior University
Alpha-fetoprotein "ring and tail" peptides
The invention relates to compounds that are analogs of a cyclic peptide, cyclo[ektovnogn], afpep, that has anti-estrotrophic activity. The analogs of the invention include peptides and peptidomimetics that inhibit estrogen receptor-dependent cell proliferation.
Albany Medical College
Compounds for proteasome enzyme inhibition
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of n-terminal nucleophile (ntn) hydrolases. The activities of those ntn having multiple activities can be differentially inhibited by the compounds described.
Onyx Therapeutics, Inc.
Compounds for regulating fak and/or src pathways
The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc
Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
Disclosed are methods of modulating erythropoiesis with arginine vasopressin receptor 1b (avpr1b) molecules, such as avpr1b agonists or antagonists. In one example, a method of stimulating erythropoiesis is disclosed including administering an effective amount of an avpr1b stimulatory molecule to a subject in need thereof, thereby stimulating erythropoiesis.
The Usa, As Represented By The Secretary, Departm- Ent Of Health And Human Service
Extracts of curcuma amada and uses thereof
The invention concerns carbon dioxide extracts of curcuma amada (mango ginger), including supercritical carbon dioxide extracts of c. Amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of bcl-2, bak, and p53 genes; inhibiting expression of the cox-2 and nf-kb genes, inhibiting production of phosphorylated target of rapamycin (tor), modulating amp-activated protein kinase (ampk), inhibiting protein kinase b (akt) signaling, modulating the ras/raf/mek/erk signaling pathway, and modulating the ras/pi3k/pten/akt/mtor signaling pathway.
Flavex Naturextrakte Gmbh
Small molecule screening for mouse satellite cell proliferation
The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject..
President And Fellows Of Harvard College
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
This invention is in the area of dosage formulations and methods of administering a cdk4/6 inhibitor for the transient protection of healthy cells, and in particular hematopoietic stem and progenitor cells (hspc), from damage associated with dna damaging chemotherapeutic agents in subjects undergoing dna damaging chemotherapeutic therapies for the treatment of proliferative disorders. In one aspect, improved protection of healthy cells is disclosed using a dosage that provides desirable pharmacokinetic and pharmacodynamic characteristics, including auc, tmax, cmax, dosage-corrected auc, and dosage-corrected cmax.
G1 Therapeutics, Inc.
Translocation and mutant ros kinase in human non-small cell lung carcinoma
In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (nsclc) that results in a fusion proteins combining part of cd74 with proto-oncogene tyrosine protein kinase ros precursor (ros) kinase has now been identified. The cd74-ros fusion protein is anticipated to drive the proliferation and survival of a subgroup of nsclc tumors.
Cell Signaling Technology, Inc.
Method of preparing induced neural stem cells reprogrammed from non-neuronal cells using hmga2
The method of producing the induced neural stem cells according to the present invention enables preparation of the induced neural stem cells from non-neuronal cells using only two inducing factors of sox2 and hmga2. Therefore, the method of the present invention can prepare induced neural stem cells in a more efficient manner than the conventional methods, which use four or five inducing factors.
Pluripotent tissue harvester and methods of manufacture thereof
Disclosed herein is a tissue harvester comprising a substrate having an airfoil shape; and a textured surface disposed upon the substrate, where the textured surface comprises a spatial array of nanometer or micrometer sized pillars of varying cross-sections. Disclosed herein too is method comprising disposing upon a substrate a textured surface; where the substrate has an airfoil shape and where the textured surface where the textured surface comprises nanometer or micrometer sized pillars; contacting the tissue harvester with biological cells whose proliferation under different conditions is desired; and disposing the tissue harvester in a flow field such that cells disposed on the tissue harvester at different locations may experience different flow fields..
University Of Florida Research Foundation, Inc.
Icos binding proteins
The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited
Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton
Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
Described herein are novel compositions comprising mt1 and/or mt2 modulators (i.e., inhibitors or activators), and methods using these agents for targeting different t-cell populations, for example, type 1 regulatory (tr1) cd4+ cells and exhausted cd8+ t-cells cells. Aspects of the invention relate to inhibitors of mt1 and/or mt2 to increase the differentiation of cd4+ cell trl1 cd4+ cells and increase in the activity of tr1 cells, e.g., to increase il-10 production.
The Brigham And Women's Hospital, Inc.